mm

About Patrick Deane

As an undergraduate of Human Biosciences at Plymouth University, aging research has been Patrick's passion for a long time now. While he has aspirations to later directly join the research effort, for now, he provides the community with educational articles, spreading knowledge of the biology behind the aging process while he himself learns.
Posts from the author

Today, we have to share some bad news about Organovo and its liver tissue bioprinting program. Present state and future steps Organovo, a biotechnology company currently valued at $45M and most well-known for researching bioprinting technologies – the creation of artificial organs – has recently announced that it is suspending its artificial liver tissue program…

A study on animals with autoimmune myocarditis was recently released in the journal Cell Reports [1], showing the impact of heart inflammation on the types of immune cell that are formed in the heart. This could have a significant impact on our understanding of cardiac aging. What is myocarditis and how is it relevant to…

Today, we want to highlight a recent human trial of the popular supplement nicotinamide riboside, a compound that has been shown in mice to restore NAD+ levels. The compound has had impressive results against some aspects of aging in mouse studies, and there is now some more data for NR in humans [1]. What is…

Note: Patrick Deane holds shares in Gensight Biologics (EPA: SIGHT). A trial with damagingly positive results Gensight Biologics, a company researching – among other things – the movement of mitochondrial genetic information to the nucleus to treat hereditary genetic diseases (a strategy that could also have an impact on aging according to the SENS Research…

Recently, Unity Biotechnology completed a phase 1 trial of its drug UBX0101. While the trial found that the drug was non-toxic and lacked serious side effects, many of its results were not statistically significant. UBX0101 UBX0101 aims to treat osteoarthritis and possibly other diseases of aging through directly targeting one of the aspects of aging…

A recent article, published in the Oxford journal Brain, categorizes and draws attention to an age-related disease that impacts the brain yet is widely unknown, even among scientists: limbic-predominant age-related TDP-43 encephalopathy (LATE) [1]. The symptoms of this disease are similar to those of Alzheimer’s disease. It causes cognitive impairment and, when presenting alongside Alzheimer’s…

A recent study has suggested that A.Ceratii, a parasite that feeds on small life forms, including the ones that form algal blooms, contains mitochondria that have no mitochondrial DNA, and at least some of this DNA is found in the parasite’s own genetic code. However, a few genes found in humans are missing and replaced…

Today, we conclude our ongoing series discussing the Hallmarks of Aging [1] by looking at the hallmark of altered intercellular communication, the change in signals between cells that can lead to some of the diseases and disabilities of aging. As an integrative hallmark, altered intercellular communication is caused by other hallmarks of aging. As a…

UNITY Biotechnologies has recently announced an expansion of its first-stage human trial of UBX0101, a drug that has been shown to have senolytic properties in mice [1] and that the company hopes will be useful in treating painful osteoarthritis of the knee. An expanded clinical trial UNITY Biotechnologies, a $495 million biotech company in the…

Another senolytic drug candidate has entered development at Unity Biotechnologies. The purpose of senolytics is to clear the body of harmful senescent cells, which accumulate with age and encourage age-related diseases to develop. A new treatment for age-related diseases of the eye Recently, UNITY Biotechnologies announced the selection of a new lead drug, UBX1967, with…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD